Pfizer's 'non obvious' Viagra patents good until 2019 to fend off Teva in US
This article was originally published in Scrip
Executive Summary
A US federal judge has upheld the validity a US method-of-use patent for Pfizer's erectile dysfunction drug, Viagra (sildenafil), a phosphodiesterase-5 (PDE5) inhibitor, thus preventing Teva Pharmaceutical Industries from marketing a generic version until October 2019.